Good morning, and welcome to the NPC Healthbiz Weekly e-newsletter from the National Pharmaceutical Congress and Chronicle Companies.
A new wave of patent expirations is expected to change the global pharmaceutical market between 2025 and 2030 dramatically. The data company Evaluate estimates that more than US$300 billion in branded prescription sales will lose exclusivity. In comparison, IQVIA projects that roughly US$220 billion in sales will be affected as major biologics encounter biosimilar competition. Big Pharma faces additional pressure in the near term, with Morgan Stanley estimating that about US$175 billion in U.S. drug revenue is at risk by the decade’s end, marking one of the steepest patent cliffs in recent memory. The Financial Times adds that, unlike previous cycles, this one involves far more biologic therapies, which could accelerate the rate of sales decline once competition begins.

Several high-profile products are already feeling the effects in 2025. According to Reuters, Johnson & Johnson’s Stelara lost U.S. exclusivity at the start of the year, opening the market to biosimilar versions of ustekinumab. Reuters also reports that Regeneron’s eye drug Eylea has come under pressure from new aflibercept biosimilars after legal setbacks prevented the company from delaying rival launches. To protect its market share, Regeneron has focused on promoting a higher-dose formulation, Eylea HD, and expanding treatment indications.
To protect existing franchises, companies are accelerating the development of new versions and improving the delivery formats of key drugs. Merck, for example, has launched a next-generation form of Keytruda, Keytruda Qlex, ahead of its main U.S. patent expiry in 2028. IQVIA reports that this cycle of patent losses will be larger than in past years, forcing companies to adopt more advanced pricing, access, and contracting strategies, especially in the biologics sector. The speed and scale of this cliff demand earlier planning and closer collaboration with payers to demonstrate product value.
Since internal pipelines cannot fill all the gaps, firms are turning more to external innovation. McKinsey & Company reports that more than 70% of new molecular entity revenues since 2018 have come from externally sourced products, underscoring the growing importance of licensing and partnerships in sustaining R&D productivity. JPMorgan Chase data shows that in the first quarter of 2025, pharma companies announced nearly US$57 billion in licensing deals and over US$25 billion in mergers and acquisitions. However, a Deloitte report warns that while research productivity has improved, sustained growth will depend on making focused, well-timed acquisitions to maintain pipeline strength.
Mergers and acquisitions are accelerating across the sector. According to Reuters, total pharma and biotech deal value reached roughly US$105 billion by mid-2025, marking the highest level in two years. At the same time, PwC notes that companies are favouring smaller, targeted acquisitions valued at between $1 billion and $5 billion to add late-stage assets quickly. Notable recent examples include AstraZeneca’s US$1 billion (initial payment US$425 million plus up to US$575 million in milestones) purchase of EsoBiotec and Roche’s acquisition of 89bio for approximately US$3.5 billion.

THIS WEEK 10/28/25
Health Canada approved Sanofi’s dupilumab injection (Dupixent) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.
Eisai Co., Ltd. and Biogen Canada Inc. announced that Health Canada issued a Notice of Compliance with Conditions for humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (Leqembi) for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have confirmed amyloid pathology.
Health Canada granted a Notice of Compliance to Apotex’s toripalimab (Loqtorzi) for the treatment of nasopharyngeal carcinoma, a rare and aggressive cancer.
Health Canada granted a Notice of Compliance to Biocon Biologics’ ustekinumab injection (Yesintek) and ustekinumab for intravenous infusion (Yesintek I.V.), a biosimilar to Stelara (ustekinumab injection) and Stelara I.V. (ustekinumab for intravenous infusion).
Join us next week at the 19th Annual National Pharmaceutical Congress!
Happening Tuesday, November 4, 2025: As Canada’s most significant stage for pharmaceutical industry leaders, the National Pharmaceutical Congress is an opportunity to learn, reflect, and network with the industry’s most prominent thought leaders and visionaries.
Join us for panels featuring reflections, ideas, and innovations from luminaries in the Life Sciences industry.
Registration includes access to all panel discussions, the Canadian Healthcare Marketing Hall of Fame reception and luncheon, and the NPC Happy Hour. Breakfast and refreshments will also be provided.
Conference recordings of the Congress will be available to registered delegates only following the meeting.
NOW, LISTEN UP: Seaford Pharmaceuticals’ Journey as a Family-owned Canadian Company
In Season 14 of the NPC Podcast, Seaford President Tamara Seales discusses navigating Canadian pharma regulations, team building, and weaving DEI into the company's fabric. Hear her in conversation with podcast hosts Mitch Shannon, Jim Shea, and Mark McElwain.
HEALTHBIZ REWIND
This feature of NPC Healthbiz Weekly looks back at some of the most insightful moments from previous NPC Podcast episodes. You can listen to the podcast here.
Dr. Rachel Asiniwasis
Founder, Dermatologist and Clinician Researcher
Origins Dermatology Centre
Regina, Sask.
Season 03, episode 07
Listen to this episode here
What are the most significant gaps in medical cultural competence? (This episode was recorded in March 2021)
I guess my view is that the general public, including Canadian healthcare practitioners, comes from diverse backgrounds and has varying levels of understanding. For example, I’ve met people who know a lot about Indigenous health, and I’ve also met people who don’t know much and have asked if my dad has lived in a teepee. Or people who didn’t know that the last residential school only closed in 1996, barely one generation ago. My dad also attended [a residential school] for nine years. So, I think it’s hard for me to identify the gaps because there’s so much diversity across Canada, but I can say there needs to be accredited learning modules. Some are extremely well done by the University of Alberta and the University of Saskatchewan, which I think could be used. I recommend them to healthcare practitioners. I know that many programs, such as nursing and medicine, do include this, but I think we need to add Indigenous cultural competency programs to our dermatology residency programs.
NEXT WEEK
It’s easy to get your no-charge subscription to NPC Healthbiz Weekly. We’ll send each issue to your phone or inbox at 6:00 a.m. sharp each Tuesday.
You are receiving this newsletter because you are a client of Chronicle Companies, attended a National Pharmaceutical Congress live event or webinar, or previously requested a subscription to one of our newsletters. If you no longer wish to subscribe to this newsletter, please email the subject line “Unsubscribe NPC Healthbiz” to health@chronicle.org.
NPC Healthbiz Weekly is published by Chronicle Companies, 701 Ellicott Street, Buffalo, N.Y. 14203. Canadian Office: 1460 The Queensway, Suite 212, Etobicoke, Ont. M8Z 1S4
Mitchell Shannon, Publisher; R. Allan Ryan, Editorial Director; John Evans, Jeremy Visser, Editors; Cristela Tello Ruiz, New Business Development; Amy Elder, Intern.
Content is copyright (c) 2025, Chronicle LifeSci America Corp., except as indicated. Are you interested in contributing to this newsletter or learning about the Chronicle’s services? Please write to us at health@chronicle.org.
Thanks for reading NPC Healthbiz Weekly. Be sure to subscribe to receive new posts directly to your inbox.





